Scandinavian and US researchers have recently published the results of a major retrospective clinical validation study showing that the IMMray PanCan-d serum biomarker microarray from Immunovia AB, Lund, Sweden, can detect early pancreatic cancer with 96% accuracy.1
Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) typically have a poor prognosis, with a 5-year survival rate of less than 10%, because the diffuse symptoms of the disease often lead to a late-stage diagnosis. It is widely accepted that the survival rate could increase significantly if localized tumors could be detected early enough to enable surgical intervention.
Carl Borrebaeck, DsC, Lund University.
The IMMray PanCan-d biomarker array incorporates a novel, 29-biomarker signature of early-stage PDAC derived from a large Danish patient cohort, including patients with early, well-defined, stage I and stage II disease progression. Results of the recently published study indicate that this signature has now been validated in both Danish and US cohorts, with a receiver operating characteristic area under the curve value of 0.96.
“Protein-based approaches, such as IMMray PanCan-d, have the best possibilities for early detection of pancreatic cancer because of its high sensitivity and requirement of only microliter sample volumes,” says senior study author Carl Borrebaeck, DSc, director of the Create Health Cancer Center and a professor of immunotechnology at Lund University. “The next step is now a well-designed prospective validation study, which Immunovia has already initiated in the form of the multicenter trial called PanFAM-1.”2
Mats Grahn, Immunovia.
“We are delighted to see the publication of this study in JCO, which confirms that IMMray PanCan-d can detect pancreatic cancer in the earliest stages with an accuracy as high as 96%, in two completely different patient cohorts collected independently on different continents,” adds Mats Grahn, CEO at Immunovia.
For more information, visit Immunovia.
References
- Mellby LD, Nyberg AP, Johansen JS, et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018;36(28):2887–2894; doi: 10.1200/jco.2017.77.6658.
- Karolinska Institutet participates in Immunovia’s PanFAM-1 prospective clinical study for early detection of pancreatic cancer using blood-based test [press release, online]. Lund, Sweden: Immunovia, 2018. Available at: www.immunovia.com/investors/press-releases/?id=3685. Accessed September 26, 2018.
